[[abstract]]As more biologic products are going off patent protection, the development of follow-on biologics products has received much attention from both biotechnology industry and the regulatory agencies. Unlike small-molecule drug products, the development of biologic products is very different and variable via the manufacture process and environment. Thus, Chow et al. (2010) suggested that the assessment of biosimilarity between biologic products focus on variability rather than average biosimilarity. In addition, it is also suggested that a probability-based criterion, which is more sensitive to variability, should be employed. In this article, we propose a probability-based asymptotic statistical testing procedure to evaluate biosim...
[[abstract]]For locally acting drug products such as nasal aerosols and nasal sprays, the 2003 US Fo...
[[abstract]]Biological drug products are therapeutic moieties manufactured by a living system or org...
When the patent of a brand-name, marketed drug expires, new, generic products are usually offered. S...
[[abstract]]As more biologic products are going off patent protection, the development of follow-on ...
[[abstract]]A biosimilar is a biological product that is highly similar to an existing approved refe...
[[abstract]]Biological products or medicines are therapeutic agents that are produced using a living...
<p>With many important biologic products due to lose patent protection in the next few years, the de...
[[abstract]]Recently, biosimilars have attracted much attention from sponsors and regulatory authori...
[[abstract]]With many important biologic products due to lose patent protection in the next few year...
Establishing comparability of the originator and its biosimilar at the structural and functional lev...
In recent years, the development of follow-on biological products (biosimilars) has received increas...
Analytical biosimilarity assessment relies on two implicit conditions. First, the analytical method ...
For approval of generic drugs, the FDA requires that evidence of bioequivalence in average bioequiva...
Average biosimilarity is investigated under a three-arm parallel design: one arm corresponds to the ...
[[abstract]]In assessing biosimilarity between two products, the question to ask is always "How simi...
[[abstract]]For locally acting drug products such as nasal aerosols and nasal sprays, the 2003 US Fo...
[[abstract]]Biological drug products are therapeutic moieties manufactured by a living system or org...
When the patent of a brand-name, marketed drug expires, new, generic products are usually offered. S...
[[abstract]]As more biologic products are going off patent protection, the development of follow-on ...
[[abstract]]A biosimilar is a biological product that is highly similar to an existing approved refe...
[[abstract]]Biological products or medicines are therapeutic agents that are produced using a living...
<p>With many important biologic products due to lose patent protection in the next few years, the de...
[[abstract]]Recently, biosimilars have attracted much attention from sponsors and regulatory authori...
[[abstract]]With many important biologic products due to lose patent protection in the next few year...
Establishing comparability of the originator and its biosimilar at the structural and functional lev...
In recent years, the development of follow-on biological products (biosimilars) has received increas...
Analytical biosimilarity assessment relies on two implicit conditions. First, the analytical method ...
For approval of generic drugs, the FDA requires that evidence of bioequivalence in average bioequiva...
Average biosimilarity is investigated under a three-arm parallel design: one arm corresponds to the ...
[[abstract]]In assessing biosimilarity between two products, the question to ask is always "How simi...
[[abstract]]For locally acting drug products such as nasal aerosols and nasal sprays, the 2003 US Fo...
[[abstract]]Biological drug products are therapeutic moieties manufactured by a living system or org...
When the patent of a brand-name, marketed drug expires, new, generic products are usually offered. S...